Are Wegovy and Ozempic the same drug?
Yes — and no. Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. The active molecule is identical. What differs is the approved dose, the approved indication, the brand name, and the price.
Ozempic was approved first, in 2017, for Type 2 diabetes management. During clinical trials, the weight loss produced as a side effect was significant enough that Novo Nordisk developed a higher-dose version — Wegovy — specifically approved for chronic weight management in 2021.
The injection formulations compared here are weekly subcutaneous injections. Wegovy also has a tablet formulation. Formulations, indications and doses must be checked separately in the current prescribing information.
Key differences between Wegovy and Ozempic
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Type 2 diabetes | Chronic weight management |
| Max approved dose | 2 mg weekly | Adults, weight reduction (injection): maintenance 1.7 mg or 2.4 mg weekly; up to 7.2 mg weekly if 2.4 mg has been tolerated for at least 4 weeks and further weight reduction is clinically indicated (US prescribing information) |
| Insurance coverage | Plan-specific; diagnosis alone does not guarantee coverage | Plan-specific |
| Monthly cost (without insurance) | Set by Novo Nordisk and your pharmacy | Set by Novo Nordisk and your pharmacy |
| Off-label for weight loss? | Yes — commonly prescribed | Approved indication |
Which is better for weight loss?
Weight loss depends on the dose and the population. In the STEP 2 trial in adults with type 2 diabetes and overweight or obesity, semaglutide 2.4 mg (the Wegovy dose) gave a mean body-weight change of −9.9% at week 68 versus −7.2% with semaglutide 1.0 mg; the Ozempic maximum dose of 2 mg was not part of that comparison (ClinicalTrials.gov NCT03552757). Results differ between studies, doses and populations, so percentages from different trials are not directly comparable.
Treatment selection and off-label use require an individualized prescriber assessment. One trial’s dose-specific result does not establish that switching brands or escalating to a maximum dose is appropriate.
Coverage depends on the product, indication and plan. Ask the insurer and pharmacy about your prescription; a diagnosis alone does not guarantee payment.
Which is better for Type 2 diabetes?
Ozempic has a type 2 diabetes indication. The suitable product and formulation depend on the full clinical situation and current label; coverage is plan-specific.
Do not infer added glucose benefit or the preferred prescription solely from different brand names or maximum doses. Discuss the exact indication, formulation and treatment goals with your prescriber.
Using CGM to track Wegovy vs Ozempic results
CGM can supply glucose observations for discussion with your prescriber, but a personal trace does not establish medication efficacy, dose adequacy or the cause of a change. Do not adjust or switch medication from sensor data; follow the prescribed plan.
CGM can supply glucose observations for discussion with your prescriber, but a personal trace does not establish medication efficacy, dose adequacy or the cause of a change. Do not adjust or switch medication from sensor data; follow the prescribed plan.
Semaglutide labeling warns of increased hypoglycemia risk with insulin or sulfonylureas. Not using insulin alone does not establish that an OTC device without clinical low-glucose alarms is suitable. Discuss medication risks and device selection with your prescriber. See our CGM discussion guide →